当前位置:首页>产品中心>单抗/多抗>Anti-Human CD30/TNFRSF8&Fc gamma RIIIA/CD16a Bispecific Reference Antibody|抗人CD30/TNFRSF8和FcγRIIIA/CD16a双特异性参考抗体(靶标:人CD30/CD16a)

Anti-Human CD30/TNFRSF8&Fc gamma RIIIA/CD16a Bispecific Reference Antibody|抗人CD30/TNFRSF8和FcγRIIIA/CD16a双特异性参考抗体(靶标:人CD30/CD16a)

  • 货号:RB9THB038106
  • 价格:面议
  • 点击:148

产品介绍

产品参数

形态Liquid
宿主种属Human
克隆性Monoclonal
抗体亚型IgG VH-V-kappa-VH'-V-lambda homodimer
纯度>95% purity as determined by SDS-PAGE.
纯化方式Protein A/G purified from cell culture supernatant.
浓度1mg/ml
内毒素水平Please contact the lab for this information.
应用ELISA, Bioactivity: FACS, Functional assay, Research in vivo
种属反应性Human
靶标CD30L receptor, Ki-1 antigen, CD30, TNFRSF8, D1S166E, Tumor necrosis factor receptor superfamily member 8, Lymphocyte activation antigen CD30, CD16a, CD16A, FCGR3A, Fc-gamma RIII-alpha, FcRIIIa, IgG F
储存缓冲液0.01M PBS, pH 7.4.
稳定性和储存Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
表达系统Mammalian Cells
登录号P28908 & P08637
背景信息Acimtamig (AFM13) is a CD30/CD16A bispecific innate cell engager. Acimtamig binds to the CD16A expressed on natural killer (NK) cells and binds to CD30 on CD30-expressing tumor cells, thereby selectively cross-linking tumor and NK cells. Acimtamig can be used for the study of eripheral T-cell lymphoma (PTCL).
别名2738880-26-5
备注For research use only. Not suitable for clinical or therapeutic use.
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Isatuximab Non-Neutralizing Recombinant Antibody |抗艾沙妥昔单抗非中和重组抗体(靶标:艾沙妥昔单抗非中和抗体) 349
Anti-Isatuximab Non-Neutralizing Recombinant Antibody |抗艾沙妥昔单抗非中和重组抗体(靶标:艾沙妥昔单抗非中和抗体) 576
Anti-Isatuximab Neutralizing Recombinant Antibody |抗艾沙妥昔单抗中和重组抗体(靶标:艾沙妥昔单抗中和抗体) 457
Anti-Isatuximab Neutralizing Recombinant Antibody |抗艾沙妥昔单抗中和重组抗体(靶标:艾沙妥昔单抗中和抗体) 307
Anti-Isatuximab Neutralizing Recombinant Antibody |抗艾沙妥昔单抗中和重组抗体(靶标:艾沙妥昔单抗中和抗体) 262
Anti-Urelumab Non-Neutralizing Recombinant Antibody |抗乌瑞鲁单抗非中和重组抗体(靶标:乌瑞鲁单抗非中和抗体) 538
Anti-Urelumab Non-Neutralizing Recombinant Antibody |抗乌瑞鲁单抗非中和重组抗体(靶标:乌瑞鲁单抗非中和抗体) 557
Anti-Urelumab Neutralizing Recombinant Antibody |抗乌瑞鲁单抗中和重组抗体(靶标:乌瑞鲁单抗中和抗体) 586
Anti-Urelumab Neutralizing Recombinant Antibody |抗乌瑞鲁单抗中和重组抗体(靶标:乌瑞鲁单抗中和抗体) 565
Anti-Urelumab Neutralizing Recombinant Antibody |抗乌瑞鲁单抗中和重组抗体(靶标:乌瑞鲁单抗中和抗体) 507
Anti-Risankizumab Neutralizing Recombinant Antibody |抗瑞莎珠单抗中和重组抗体(靶标:瑞莎珠单抗中和抗体) 296
Anti-Risankizumab Neutralizing Recombinant Antibody |抗瑞莎珠单抗中和重组抗体(靶标:瑞莎珠单抗中和抗体) 405
Anti-Risankizumab Neutralizing Recombinant Antibody |抗瑞莎珠单抗中和重组抗体(靶标:瑞莎珠单抗中和抗体) 615
Anti-Risankizumab Neutralizing Recombinant Antibody |抗瑞莎珠单抗中和重组抗体(靶标:瑞莎珠单抗中和抗体) 282
Anti-Ranibizumab Non-Neutralizing Recombinant Antibody |抗雷珠单抗非中和重组抗体(靶标:雷珠单抗非中和抗体) 503
Anti-Ranibizumab Non-Neutralizing Recombinant Antibody |抗雷珠单抗非中和重组抗体(靶标:雷珠单抗非中和抗体) 384
Anti-Ranibizumab Non-Neutralizing Recombinant Antibody |抗雷珠单抗非中和重组抗体(靶标:雷珠单抗非中和抗体) 493
Anti-Ranibizumab Neutralizing Recombinant Antibody |抗雷珠单抗中和重组抗体(靶标:雷珠单抗中和抗体) 358
Anti-Ranibizumab Neutralizing Recombinant Antibody |抗雷珠单抗中和重组抗体(靶标:雷珠单抗中和抗体) 488
Anti-Ranibizumab Neutralizing Recombinant Antibody |抗雷珠单抗中和重组抗体(靶标:雷珠单抗中和抗体) 281
总计 33037 个记录,共 1652 页,当前第 1645 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周五每天9:00-17:00